These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35890048)

  • 1. Improving Drug Sensitivity of HIV-1 Protease Inhibitors by Restriction of Cellular Efflux System in a Fission Yeast Model.
    Zhang J; Li Q; Kawashima SA; Nasr M; Xue F; Zhao RY
    Pathogens; 2022 Jul; 11(7):. PubMed ID: 35890048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Agent and Fixed-Dose Combination HIV-1 Protease Inhibitor Drugs in Fission Yeast (
    Zhang J; Vernon K; Li Q; Benko Z; Amoroso A; Nasr M; Zhao RY
    Pathogens; 2021 Jun; 10(7):. PubMed ID: 34202872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of A Fission Yeast Cell-Based Platform for High Throughput Screening of HIV-1 Protease Inhibitors.
    Benko Z; Zhang J; Zhao RY
    Curr HIV Res; 2019; 17(6):429-440. PubMed ID: 31782368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Protease in the Fission Yeast Schizosaccharomyces pombe.
    Benko Z; Elder RT; Li G; Liang D; Zhao RY
    PLoS One; 2016; 11(3):e0151286. PubMed ID: 26982200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fission yeast cell-based system for multidrug resistant HIV-1 proteases.
    Benko Z; Liang D; Li G; Elder RT; Sarkar A; Takayama J; Ghosh AK; Zhao RY
    Cell Biosci; 2017; 7():5. PubMed ID: 28096973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of HIV-1 genome in fission yeast Schizosaccharomyces pombe.
    Nkeze J; Li L; Benko Z; Li G; Zhao RY
    Cell Biosci; 2015; 5():47. PubMed ID: 26309721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
    Lambert-Niclot S; Flandre P; Canestri A; Peytavin G; Blanc C; Agher R; Soulié C; Wirden M; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Feb; 52(2):491-6. PubMed ID: 18039922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.
    Aoki M; Das D; Hayashi H; Aoki-Ogata H; Takamatsu Y; Ghosh AK; Mitsuya H
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.
    Raugi DN; Smith RA; Gottlieb GS;
    J Virol; 2016 Jan; 90(2):1062-9. PubMed ID: 26559830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
    Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The L33F darunavir resistance mutation acts as a molecular anchor reducing the flexibility of the HIV-1 protease 30s and 80s loops.
    Kuiper BD; Keusch BJ; Dewdney TG; Chordia P; Ross K; Brunzelle JS; Kovari IA; MacArthur R; Salimnia H; Kovari LC
    Biochem Biophys Rep; 2015 Jul; 2():160-165. PubMed ID: 29124158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
    Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
    J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
    Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
    Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors.
    Lin YC; Happer M; Elder JH
    J Virol; 2013 Aug; 87(15):8524-34. PubMed ID: 23720716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination.
    Augustine R; Ashkenazi DL; Arzi RS; Zlobin V; Shofti R; Sosnik A
    Acta Biomater; 2018 Jul; 74():344-359. PubMed ID: 29723705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
    Yedidi RS; Garimella H; Aoki M; Aoki-Ogata H; Desai DV; Chang SB; Davis DA; Fyvie WS; Kaufman JD; Smith DW; Das D; Wingfield PT; Maeda K; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3679-88. PubMed ID: 24752271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
    Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.